AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST.

Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in six patients from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), announce development plans for expansion in autoimmune diseases, and provide a brief update of the ongoing commercial launch of AUCATZYL®.

A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at . A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

The live event will be held in New York City. To inquire about in-person attendance please email:

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit

Contact:

Amanda Cray 

 

 

Olivia Manser 

8 

 



EN
01/04/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
EXO EXOR N.V.
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
ECMPA EUROCOMMERCIAL PROPERTIES NV
13h / 30m 13h / 30m 1 EN
Michiel Declercq
  • Michiel Declercq
AUTL Autolus Therape...

Autolus Aucatzyl gains EC approval in r/r adult ALL

Autolus announced that the European Commission (EC) has granted marketing authorization for Aucatzyl (obe-cel, CD19 CAR-T) for the treatment of adults aged 26+ years with r/r B-ALL. Autolus will now evaluate market entry opportunities in the EU, which we expect to take place on a country-by-country basis – the company has previously indicated that the initial focus in the EU will be on Germany. More broadly, the US commercial launch in r/r adult ALL began in early 2025, and the first quarter of ...

AUTL AUTOLUS THERAPEUTICS ADS
13h / 41m 13h / 41m 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therape...

July 21, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock opti...

July 15, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus Longer follow up at EHA maintains Aucatzyl's benefit in r/r ad...

Autolus announced updated long term data (approx. 3 years of follow up) from the phase 2 (FELIX) study of Aucatzyl (CD19 CAR-T) in r/r adult ALL to be presented at the European Hematology Association (EHA) conference, being held 12-15 June. The updated results demonstrate that Aucatzyl has maintained its benefit without the need for additional therapy with an additional 11 months of follow up as 38.4% of responders are in ongoing remission (vs. 40% at 21.5 months median follow up). We believe th...

AUTL AUTOLUS THERAPEUTICS ADS
06/12/25 June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch